Ondansetron

Introduction Overview

Generic Name

ondansetron

Brand Name

Zofran ODT

Dosage Form

orally disintegrating tablet (ODT)

Drug Class

5HT3 receptor antagonists

Pharmacokinetics

Absorption:
Ondansetron administered as orally disintegrating tablets is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations are typically reached within 1 to 2 hours after oral administration. The ODT formulation facilitates dissolution on the tongue, which enhances patient compliance, especially in those with difficulty swallowing. Food intake may slightly delay the time to peak concentration but does not significantly alter the overall bioavailability. The absolute bioavailability of oral ondansetron is approximately 60% due to hepatic first-pass metabolism.

Distribution:
Ondansetron is widely distributed throughout the body after absorption, with a volume of distribution (Vd) ranging from 1.9 to 2.5 L/kg. It demonstrates moderate plasma protein binding, approximately 70% to 76%, primarily to albumin. The drug crosses the blood-brain barrier and distributes into the central nervous system, underlying its antiemetic effects. Ondansetron also crosses the placenta and is present in breast milk, though in small amounts.

Metabolism:
Ondansetron undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme system, especially CYP3A4, CYP2D6, and CYP1A2 isoenzymes. Hepatic metabolism involves hydroxylation and subsequent conjugation to form inactive metabolites, mainly glucuronide and sulfate conjugates. Drug interactions affecting these enzymes can modify plasma levels of ondansetron, potentially impacting efficacy and safety.

Elimination:
The elimination half-life of ondansetron ranges from 3 to 6 hours in healthy adults, though it may be prolonged in patients with hepatic impairment. The majority of the drug is excreted as metabolites via the urine (approximately 70%) and to a lesser extent in the feces. Renal clearance is minor since ondansetron is extensively metabolized. Hepatic and renal function impairment can lead to altered pharmacokinetics necessitating careful dosing in these populations.

Dosage Forms

Available Dosage Forms:
- Orally disintegrating tablets (ODT): available typically in strengths such as 4 mg and 8 mg for adult and adolescent use.

Dosages for Adults and Adolescents:
- For prevention of chemotherapy-induced nausea and vomiting: 8 mg orally, administered 30 minutes prior to chemotherapy; additional doses of 8 mg can be given 8 and 16 hours after the first dose as per clinical guidelines.
- For prevention of postoperative nausea and vomiting: a single dose of 4 mg to 8 mg given 1 hour before anesthesia.
- For prevention of radiation-induced nausea and vomiting: 8 mg administered 1 to 2 hours before radiation therapy, with doses repeated every 8 hours as needed.

Specific Patient Populations:
- Pediatric Use: Not approved in children under 4 years of age.
- Hepatic Impairment: The dose should be reduced to 4 mg for adult patients with severe hepatic impairment due to prolonged half-life.
- Geriatric Patients: Generally, no dose adjustment is required, but close monitoring is recommended due to potential altered pharmacokinetics.

Note: The brand Zofran ODT has been discontinued in the U.S., although generic oral disintegrating tablet versions of ondansetron are available and may differ slightly in formulation and strength.

Mechanism Of Action

Ondansetron is a selective serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist that works both peripherally and centrally to prevent nausea and vomiting. The drug blocks the action of serotonin, a natural substance involved in triggering the vomiting reflex, by binding to 5-HT3 receptors located on vagal nerve terminals in the gastrointestinal tract and in the chemoreceptor trigger zone (CTZ) of the brain.

The primary molecular mechanism involves competitively inhibiting serotonin binding to 5-HT3 receptors, which are ligand-gated ion channels that mediate neurotransmission related to emesis. By blocking these receptors, ondansetron disrupts the vagal afferent signaling to the brainstem vomiting center and reduces the stimulus that leads to the vomiting reflex.

Cellularly, ondansetron prevents depolarization of vagal afferent neurons by inhibiting the influx of sodium and calcium ions post-serotonin binding, thereby reducing neuronal excitability. This leads to diminished activation of the nucleus tractus solitarius and the vomiting center in the medulla oblongata.

Clinically, ondansetron's antiemetic effect is particularly valuable during chemotherapy, radiation therapy, and postoperative recovery where serotonin release from enterochromaffin cells is commonly elevated. Compared to other antiemetics such as dopamine antagonists or antihistamines, ondansetron has a favorable side effect profile and specific receptor targeting that reduces CNS sedation.

Research evidence supports the efficacy of ondansetron in reducing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV), with clinical trials demonstrating significant reduction in emetic episodes and improved patient quality of life. Its advent established the 5-HT3 receptor antagonist class as the standard of care in emesis prevention.

Pharmacological Actions

Selective antagonism of 5-HT3 serotonin receptors on vagal nerve terminals and in the CNS.
Blocking serotonin-mediated activation of the vomiting reflex pathway.
Inhibition of vagal afferent nerve depolarization to reduce emetic signaling.
Prevention of chemotherapy, radiation, and surgery-induced nausea and vomiting.
Reduction in neurotransmission within the chemoreceptor trigger zone (CTZ).
Dose-dependent antiemetic effect with rapid onset of action.
Minimal sedative properties compared to other antiemetic drug classes.
Favorable tolerability and safety profile in clinical use.
No significant anticholinergic or antidopaminergic effects.
Potential cardiac electrophysiologic effects, including QT interval prolongation at high doses.

Therapeutic Or Clinical Uses

Prevention of nausea and vomiting caused by cytotoxic chemotherapy in adults and adolescents.
Prevention of postoperative nausea and vomiting (PONV) following surgical procedures.
Prevention of radiation-induced nausea and vomiting (RINV) during radiotherapy.
Off-label use in prevention and treatment of nausea and vomiting in pregnancy under clinical discretion.
Use in combination therapy with other agents (e.g., corticosteroids) for enhanced antiemetic efficacy during chemotherapy.
Management of nausea and vomiting refractory to other antiemetics.
Symptomatic treatment of nausea associated with gastroenteritis or other gastrointestinal disorders.
Prevention of nausea and vomiting associated with diagnostic and therapeutic procedures.

Side Or Adverse Effects

Common adverse effects include headache, which can be mild to moderate in intensity.
Gastrointestinal disturbances such as diarrhea or constipation may occur.
Fatigue, malaise, and feelings of general unwellness are reported.
Respiratory-related effects including shortness of breath, rapid breathing, and palpitations have been observed.
Possible dizziness, lightheadedness, or fainting due to cardiac rhythm changes.
Serious but rare hypersensitivity reactions including anaphylaxis with symptoms of hives, swelling, and difficulty breathing.
Potential for QT interval prolongation leading to arrhythmias such as torsades de pointes in predisposed individuals.
Serotonin syndrome risk when used concomitantly with other serotonergic drugs; symptoms include agitation, hallucinations, muscle stiffness, and autonomic instability.
Abdominal pain, bloating, or changes in bowel habits may suggest gastrointestinal obstruction or functional disorders.
Injection site reactions (for injectable formulations) such as pain, redness, or swelling.
Transient liver enzyme elevations have been noted in some patients.
Rare reports of extrapyramidal symptoms, though uncommon with ondansetron's receptor profile.
Hypokalemia or hypomagnesemia may exacerbate cardiac effects.
Potential hypersensitivity to ingredients such as phenylalanine in the orally disintegrating tablets.
Overdose symptoms can include severe constipation, headache, and cardiac arrhythmias.

Precautions

Use cautiously in patients with a history of cardiac arrhythmias, particularly congenital long QT syndrome.
Assess electrolyte abnormalities such as hypokalemia or hypomagnesemia before administration.
Monitor patients with severe hepatic impairment closely and adjust dose accordingly.
Patients with phenylketonuria (PKU) should avoid the orally disintegrating tablet formulation due to phenylalanine content.
Caution when administering concomitantly with other drugs that prolong the QT interval.
Avoid use in children under 4 years, as safety and efficacy are not established.
Inform patients about the potential for serotonin syndrome when taken with serotonergic medicines.
Advise patients to report any symptoms of allergic reactions or cardiac symptoms immediately.
Avoid excessive or more frequent dosing beyond recommended schedules to minimize adverse effects.
Caution in pregnant or breastfeeding women; consult healthcare providers regarding risks and benefits.
Use with care in patients with gastrointestinal obstructions or alterations in GI anatomy.
Evaluate polypharmacy and drug interactions thoroughly prior to initiating ondansetron treatment.
Advise patients regarding proper administration technique for ODT to prevent dosing errors.
Conduct periodic ECG monitoring in patients at risk of arrhythmias during therapy.
Use caution in elderly patients due to potential for altered pharmacokinetics and comorbidities.

Warnings

Do not use Zofran ODT if allergic to ondansetron or similar 5-HT3 antagonists such as dolasetron, granisetron, or palonosetron.
Serious cardiac effects including QT prolongation and torsades de pointes have been reported; use caution in patients with underlying cardiac conditions.
Risk of serotonin syndrome when combined with other serotonergic agents; requires immediate medical attention if symptoms develop.
Severe hypersensitivity reactions including anaphylaxis can occur; discontinue use immediately if signs appear.
Avoid use with apomorphine due to risk of profound hypotension and loss of consciousness.
Zofran ODT contains phenylalanine, which may be harmful in patients with phenylketonuria.
Not approved for use in children younger than 4 years due to lack of safety data.
Should be used under medical supervision especially in patients with hepatic impairment.
Potential for severe constipation or bowel obstruction; monitor gastrointestinal function during treatment.
Consult healthcare provider if pregnancy or breastfeeding before initiating ondansetron therapy.
Do not exceed the recommended dose or frequency; overdosing can increase risk of adverse effects.
Drug interactions that enhance QT prolongation increase the risk of serious cardiac events.
Avoid sharing medication with others; use only for prescribed indication.
Report any symptoms of heart attack immediately, including chest pain, jaw pain, or profuse sweating.
Patients should be monitored for signs of electrolyte imbalance when on Zofran ODT therapy.

Contraindication

Known hypersensitivity to ondansetron or any component of the formulation.
History of allergic reactions to other 5-HT3 receptor antagonists such as dolasetron, granisetron, or palonosetron.
Concomitant use with apomorphine due to risk of significant hypotension and loss of consciousness.
Patients with congenital long QT syndrome unless benefit outweighs risk with monitored care.
Severe hepatic impairment requiring dose adjustment and careful monitoring; contraindicated in some cases without supervision.
Phenylketonuria patients should avoid orally disintegrating tablet due to phenylalanine content.
Patients with known cardiac conduction abnormalities where ondansetron may exacerbate arrhythmias without supervision.
Children younger than 4 years as safety and efficacy have not been established in this population.

Drug Interactions

Apomorphine: co-administration contraindicated due to risk of profound hypotension and loss of consciousness.
Drugs that prolong QT interval such as certain antiarrhythmics, antipsychotics, and macrolide antibiotics can increase risk of cardiac arrhythmias when combined.
Serotonergic agents including SSRIs, SNRIs, triptans, and MAO inhibitors increase risk of serotonin syndrome when used concomitantly.
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ondansetron plasma concentrations by reducing metabolism.
CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease ondansetron efficacy by increasing metabolic clearance.
Other antiemetics or CNS depressants may have additive sedative or CNS effects.
Stimulants and opioids may increase risk of serotonin syndrome when combined with ondansetron.
Herbal supplements such as St. John's Wort may induce CYP enzymes altering ondansetron levels.
Lithium may enhance serotonergic activity and increase risk of serotonin syndrome.
Concurrent use with diuretics or other agents affecting electrolyte balance may exacerbate cardiac risk due to hypokalemia or hypomagnesemia.
Drugs metabolized by CYP2D6 may have altered metabolism when given with ondansetron due to enzyme inhibition.
Co-administration with other chemotherapy agents requires careful scheduling to manage cumulative toxicity.
Potential interaction with medications used for Parkinson’s disease requiring monitoring of neurological status.
Dexamethasone and other corticosteroids are often used concomitantly to enhance antiemetic effect with no significant pharmacokinetic interference.
Alcohol may increase risk of central nervous system side effects such as dizziness and fatigue.

Preparations Of The Drug

Orally disintegrating tablets (ODT) available in 4 mg and 8 mg strengths for ease of administration without water.
Standard oral tablets of ondansetron in various strengths (4 mg, 8 mg) for prevention and treatment of nausea and vomiting.
Oral soluble films designed to dissolve rapidly on the tongue as alternative to ODT.
Injectable formulations (intravenous or intramuscular) for rapid onset in acute settings, typically in hospital use.
Oral liquid formulations for pediatric and patients with swallowing difficulties.
Combination products including ondansetron with dexamethasone for enhanced antiemetic therapy in chemotherapy patients.
Generic versions of ondansetron in ODT and other formulations available following discontinuation of Zofran ODT brand.
Packaging typically includes blister packs for ODTs to maintain stability and allow dry storage until use.
Available in single-dose packaging to minimize contamination and ensure dosing accuracy.
Storage instructions specify keeping tablets in original blister packs at room temperature away from moisture and light.
Measuring devices provided with liquid preparations to facilitate accurate dosing.
Formulations free of commonly allergenic excipients suitable for most patients except those with PKU due to phenylalanine content in some ODTs.
All preparations are prescription only and should be used under medical supervision.
Compatibility information needed for mixing injectable form with other intravenous fluids or medications.
Variations in formulation exist internationally depending on licensed product availability.